FGP
PRAX icon

Freestone Grove Partners’s Praxis Precision Medicines PRAX Stock Holding History

Freestone Grove Partners’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,269
Closed -$438K – 897
2025
Q3 		$438K Buy
+8,269
New +$401K ﹤0.01% 555
2025
Q1 		– Sell
-3,080
Closed -$237K – 746
2024
Q4 		$237K Buy
+3,080
New +$223K ﹤0.01% 509

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Freestone Grove Partners's PRAX Position: Q4 2025 in Review

Freestone Grove Partners sold out of Praxis Precision Medicines (PRAX) in Q4 2025, closing a stake of 8,269 shares — an estimated $438K sold.

Freestone Grove Partners first reported a position in PRAX in Q4 2024 and held it in 2 quarters. The position peaked at $438K in Q3 2025. 250 funds tracked by Wall St. Rank hold PRAX as of Q4 2025.

  • Freestone Grove Partners reported no remaining Praxis Precision Medicines position as of Q4 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 8,269 Praxis Precision Medicines shares in Q4 2025, an estimated $438K.
  • Freestone Grove Partners first reported a position in Praxis Precision Medicines in Q4 2024 and held it in 2 quarters.
  • Freestone Grove Partners's Praxis Precision Medicines position peaked at $438K in Q3 2025.
  • 250 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2025.

Based on Freestone Grove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.